Data / Form D filings / Nexo Therapeutics, Inc.
Nexo Therapeutics, Inc.: Form D filings
Nexo Therapeutics, Inc., a biotechnology company in Littleton, CO, filed 4 Form D notices with the SEC between 2022 and 2026. The latest, on March 27, 2026, reports $60 million sold of a $60 million offering to 7 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 11757 W. KEN CARYL AVENUE SUITE F, 520, Littleton, CO, 80127
- Phone
- (303) 868-6790
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2022
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1955319
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | Amendment | $60,000,000 | $60,000,000 | 7 | Nov 15, 2022 | sec.gov | |
| Sep 17, 2025 | Amendment | $60,000,000 | $52,500,001 | $7,499,999 | 7 | Nov 15, 2022 | sec.gov |
| Sep 13, 2024 | Amendment | $60,000,000 | $45,000,000 | $15,000,000 | 6 | Nov 15, 2022 | sec.gov |
| Nov 21, 2022 | New notice | $60,000,000 | $30,000,000 | $30,000,000 | 6 | Nov 15, 2022 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Andrew Phillips | Executive Officer, Director | |
| Ali Behbahani | Director | |
| Carlo Rizzuto | Director |
Other biotechnology companies in Colorado that filed recently
- GelSana Therapeutics, Inc. $4.4 million · Oct 8, 2026
- Renovare Therapeutics, Inc. $100,000 · Oct 2, 2026
- EnteroTrack, LLC $2 million · Sep 25, 2026
- Shiverbright Technologies, Inc. $200,000 · Aug 7, 2026
Every Form D from the week of Mar 23, 2026 · All recent filings in Colorado · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Nexo Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.